Jefferies Reiterates Buy Rating on Acrivon Therapeutics Inc (ACRV) Mar 2, 2026 03:39PM
Acrivon to present ACR-368 endometrial cancer data at ESGO congress Jan 23, 2026 08:13AM
Acrivon Therapeutics Inc (ACRV) PT Raised at Piper Sandler on 'Positive Clinical Data' Jan 9, 2026 08:06AM
Acrivon reports positive endometrial cancer trial data, expands to EU Jan 8, 2026 07:32AM
Acrivon's (ACRV) ORR, mDoR Results are Competitive - Citizens Nov 17, 2025 04:27AM


Nov 13, 2025 06:46PM Acrivon Therapeutics, Inc. (ACRV) Tops Q3 EPS by 69c
Oct 22, 2025 04:27PM Acrivon Therapeutics presents preclinical data for ACR-2316 at cancer conference
Sep 17, 2025 04:08AM Citizens JMP Reiterates Market Outperform Rating on Acrivon Therapeutics Inc (ACRV)
Aug 15, 2025 05:53AM Citizens JMP Reiterates Market Outperform Rating on Acrivon Therapeutics Inc (ACRV)
Aug 13, 2025 06:10PM Acrivon Therapeutics, Inc. (ACRV) Tops Q2 EPS by 54c
May 30, 2025 05:01AM Citizens JMP: Standard of Care Modifying Regimens at ASCO 2025
May 15, 2025 05:41PM Acrivon Therapeutics, Inc. (ACRV) Tops Q1 EPS by 50c
May 15, 2025 07:26AM Cantor Fitzgerald Reiterates Overweight Rating on Acrivon Therapeutics Inc (ACRV)
May 5, 2025 07:06AM Piper Sandler Assumes Acrivon Therapeutics Inc (ACRV) at Overweight
Apr 7, 2025 04:05PM Acrivon Therapeutics (ACRV) Appoints Mansoor Raza Mirza as Chief Medical Officer
Mar 28, 2025 06:45AM H.C. Wainwright Reiterates Buy Rating on Acrivon Therapeutics Inc (ACRV)
Mar 26, 2025 06:47AM Acrivon Therapeutics Inc (ACRV) PT Lowered to $19 at H.C. Wainwright
Mar 26, 2025 06:44AM Cantor Fitzgerald Reiterates Overweight Rating on Acrivon Therapeutics Inc (ACRV)
Mar 26, 2025 04:05AM Citizens JMP Reiterates Market Outperform Rating on Acrivon Therapeutics Inc (ACRV)
Mar 24, 2025 05:41AM Citizens JMP Reiterates Market Outperform Rating on Acrivon Therapeutics Inc (ACRV)
Feb 5, 2025 08:00AM Acrivon Therapeutics (ACRV) Granted FDA Breakthrough Device Designation for ACR-368
Jan 31, 2025 06:04AM Cantor Fitzgerald Starts Acrivon Therapeutics Inc (ACRV) at Overweight
Nov 14, 2024 07:53AM Acrivon Therapeutics Inc (ACRV) PT Lowered to $27 at BMO Capital
Nov 13, 2024 05:23PM Acrivon Therapeutics, Inc. (ACRV) Tops Q3 EPS by 15c
Oct 11, 2024 08:03AM Acrivon Therapeutics (ACRV) Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity
Sep 16, 2024 08:42AM TD Cowen Reiterates Buy Rating on Acrivon Therapeutics Inc (ACRV)
Sep 16, 2024 07:50AM Piper Sandler Reiterates Overweight Rating on Acrivon Therapeutics Inc (ACRV)
Sep 16, 2024 07:14AM H.C. Wainwright Reiterates Buy Rating on Acrivon Therapeutics Inc (ACRV)
Sep 16, 2024 06:46AM Ladenburg Thalmann Upgrades Acrivon Therapeutics Inc (ACRV) to Buy, 'Impressive Endometrial Responses'
Aug 14, 2024 10:04AM BMO Capital Reiterates Outperform Rating on Acrivon Therapeutics Inc (ACRV)
Aug 13, 2024 10:17AM Acrivon Therapeutics, Inc. (ACRV) Tops Q2 EPS by 23c
Aug 13, 2024 10:17AM Acrivon Therapeutics, Inc. (ACRV) Tops Q2 EPS by 23c